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Abstract
We recently reported the discovery of UNC1215, a potent and selective chemical probe for the
L3MBTL3 methyllysine reader domain. In this article, we describe the development of structure-
activity relationships (SAR) of a second series of potent L3MBTL3 antagonists which evolved
from the structure of the chemical probe UNC1215. These compounds are selective for L3MBTL3
against a panel of methyllysine reader proteins, particularly the related MBT family proteins,
L3MBTL1 and MBTD1. A co-crystal structure of L3MBTL3 and one of the most potent
compounds suggests that the L3MBTL3 dimer rotates about the dimer interface to accommodate
ligand binding.
Introduction
Histone post translational modifications such as lysine methylation play an important role in
the function of chromatin by creating binding sites for reader proteins. This binding event
leads to downstream signalling via the recruitment and stabilization of chromatic template
machinery and is an essential step in the regulation of chromatin and gene expression.1, 2
Histone lysine methylation can signal either the activation3, 4 or repression5-7 of gene
transcription, depending on the site and degree of methylation.8 Lysine methylation has been
identified in various positions of the histone tails, mainly on histone 3 at positions H3K4
(lysine 4), H3K9, H3K27, H3K36, H3K79 and on histone four at position H4K20.9 The ε-
amino group of a lysine at any of these positions can be mono (me1), di (me2) or
trimethylated (me3), thus changing the chemical properties of this residue from a small,
relatively “hard” positive charge to a more diffuse, “soft” and polarizable positive charge in
the case of Kme3.10 In most cases, the binding site of this methylated residue is a
hydrophobic ‘aromatic cage’, a conserved structural motif in almost all reader proteins.11 In
our previous studies, we have focussed on the recognition of lysine methylation by MBT
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domain methyllysine readers, a subclass in the ‘Royal family’ of proteins that includes the
proteins L3MBTL1, L3MBTL3, and MBTD1 among others.12, 13 While these proteins have
been associated with haematopoiesis14 and cancer biology,15, 16 their exact biological
mechanisms still require elucidation. For this reason, we have endeavoured to identify small
molecule chemical probes that would facilitate further study and understanding of these
proteins.17 To date, we have reported the discovery of weak small molecule inhibitors of
L3MBTL1 such as UNC669,18, 19 and have most recently identified a potent and selective
chemical probe, UNC1215, for the L3MBTL3 methyllysine reader domain (Figure 1.).20
Interestingly, the high potency and selectivity of UNC1215 can be explained by its co-
crystal structure with L3MBTL3 which shows that UNC1215 binds as a 2:2 dimer with the
protein.20 This was the first published evidence of L3MBTL3 dimerization and has
prompted further studies in our group. Here we report a second series of L3MBTL3
inhibitors, their structure-activity relationships and their potential unique interactions with
the L3MBTL3 dimer.
Results and discussion
In our efforts to develop additional, novel inhibitors of the methyllysine reader, L3MBTL1,
we simulated putative apohomodimer conformations of L3MBTL1 and L3MBTL3 using a
recently developed scheme for free energy computations.21 In each case, we observed stable
homodimers with more compact ligand pockets than those observed in the UNC1215-
L3MBTL3 co-crystal structure.20 Based on this observation, new small molecule ligands
were proposed as possible ligands that could fit within the more compact homodimer
pockets while preserving the dibasic character of UNC1215, which we knew was required
for potent dimer binding. Following Scheme 1, we synthesised the dibasic compound
UNC2533 (1) and identified it as a potent inhibitor of the L3MBTL3 methyllysine reader
domain. In vitro evaluation of UNC2533 in an AlphaScreen® methylated histone peptide
competition assay22 yielded an IC50 of 62±7.2 nM for L3MBTL3 which is within three-fold
of the chemical probe UNC1215 (IC50 = 24±7.6 nM, Table 1).a The activity of UNC2533
was confirmed by isothermal titration calorimetry (ITC), to give a Kd of 0.37 μM which is
also within 3-fold of the reported dissociation constant of UNC1215 (Kd = 0.12 μM).20
Biological screening of UNC2533 against the other readers in our panel (Table 1) showed a
similar selectivity profile to UNC1215. UNC2533 binds L3MBTL1 weakly (IC50 = 14±0.0
μM) with a similar affinity to the L3MBTL1 inhibitor UNC66918, 19 (IC50 = 21±1.2 μM).
The weak binding affinity for L3MBTL1 was also confirmed by ITC (Kd = 19.0 μM),
showing that UNC2533 is 50 times more selective for L3MBTL3 over L3MBTL1. As the
L3MBTL1 monomer is known to bind UNC669 via key interactions between the pyrrolidine
and the aromatic reader pocket,18 it is reasonable to suggest that one or both of the
pyrrolidines in UNC2533 is responsible for its weak L3MBTL1 activity. UNC2533 also
displays weak activity against the other royal family protein MBTD1, as well as 53BP1, a
member of the Tudor domain family. Other readers from the chromodomain family (CBX7),
the Tudor domain family (UHRF1), and the PHD finger family of zinc-binding proteins
(PHF23 and Jarid1A) did not bind to UNC2533 (IC50 > 30 μM).
The X-ray co-crystal structure of UNC2533 and L3MBTL3
To investigate the potential binding mode of UNC2533 to L3MBTL3, the X-ray co-crystal
structure of the complex was determined and refined to 2.3Å (PDB ID: 4L59). Despite being
a smaller molecule than UNC1215, UNC2533 also binds L3MBTL3 as a 2:2 complex. Each
molecule of UNC2533 bridges the L3MBTL3 dimer interface by interacting with domain 1
of one monomer and the presumed histone methyllysine binding domain (domain 2) of the
other monomer (Figure 2a). The binding interaction to domain 2 is primarily mediated by a
strong hydrogen bond (2.6Å) between the carboxylate oxygen of D381 and the pyrrolidine
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nitrogen of the (pyrrolidinyl)piperidine moiety (Figure 2b). Additional hydrophobic contacts
and a cation-π interaction between the positively charged pyrrolidine nitrogen and the
domain 2 aromatic cage strengthen binding. The interaction of UNC2533 with domain 1 is
mediated by a second hydrogen bond (2.8Å) between the carboxylate oxygen of D274 and
the C2-linked pyrrolidine nitrogen. Further hydrophobic contacts between the pyrrolidine
ring and Y301 reinforce binding in this pocket. Atomic distances for the key binding
interactions in the UNC1215-L3MBTL3 complex20 and the UNC2533-L3MBTL3 complex
were measured using MOE software.23 All key contacts between the ligand and the protein
were very similar in distance and strength (Supplementary Table 5). This result was
surprising as UNC2533 is significantly smaller in size than UNC1215. Measurement of the
intramolecular distance between the two basic nitrogens in UNC2533 is 10.4Å. The
equivalent intramolecular distance for the UNC1215 molecule is 13.1Å. This difference
indicates that a change in the conformation of the L3MBTL3 dimer must have occurred to
maintain its bonding interactions with the smaller inhibitor, UNC2533.
To compare the UNC1215-L3MBTL3 complex with the UNC2533-L3MBTL3 complex we
aligned selected backbone chains with Kabsch's method24 as implemented in the molecular
dynamics program VMD25. Visualization of the entire 2:2 complex shows that the dimer
interface has rotated slightly such that only one of the two monomers in the UNC2533-
L3MBTL3 complex is aligned with the UNC1215-L3MBTL3 complex (Figure 3). For the
“aligned” monomers, there is very little structural variation in the domain 1 and domain 2
binding pockets. Upon closer inspection of the domain 2 (methyllysine) binding pocket we
found that all of the key residues are closely aligned with the exception of some flexibility in
the side chains (Figure 4a). Similarly, the conformation of the domain 1 binding pocket is
also well conserved, with the exception of the E410 side chain which has flipped its
orientation due to a steric clash with the phenyl ring of UNC1215 (Figure 4b). In contrast,
all of the key residues in the “misaligned” monomers have shifted. Measurement of the
distances between the alpha carbons of residue pairs in the binding site of each crystal
structure shows a shift of between 2.4 and 4.6Å (Figure 4c-d, Supplementary Table 6). The
same results were observed when the alternate monomer was aligned using Kabsch's
method24. These findings reveal that the L3MBTL3 dimer primarily accommodates binding
of the smaller UNC2533 molecule by rotating the two L3MBTL3 monomers at the dimer
interface rather than altering the conformation of the protein backbone in the ligand binding
site. This flexibility at the dimer interface could be a mechanism that endogenous
L3MBTL3 uses to read different histone sequences however whether this observation is
truly important is the subject of ongoing studies.
Structure-activity relationships
As the central core of the UNC2533 molecule is structurally distinct from UNC1215, we
further investigated how changes in this structure would affect its activity and selectivity for
L3MBTL3. We first synthesised a series of compounds that explored modifications to the
(pyrrolidinyl)piperidine, the pyrrolidine, and the C2-linker. Synthesis was performed
following the methods exemplified in Scheme 1 or Scheme 2 and as described in the
supplemental material. Briefly, compounds were synthesised from the commercially
available 1-bromo-4-(2-bromoethyl)benzene via an alkylation reaction followed by cross
coupling (Scheme 1). For Buchwald couplings, the reaction conditions were improved by
employing a RuPhos/RuPhos pre-catalyst system, with NaOt-Bu as the base and
tetrahydrofuran as the solvent.26 These conditions were more suitable for the coupling of
cyclic amines affording the desired products in superior yields (18-98%) within a shorter
reaction time. Under microwave irradiation, complete conversion to the product was often
observed by LCMS after 10 minutes of heating. If the dibromo starting material was
unavailable, compounds were synthesised from the acid via an initial amide coupling. A
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Buchwald coupling followed by reduction of the amide with LiAlH4 gave the final dibasic
compounds (Scheme 2.).
The biological activity of all compounds was primarily evaluated against our reader panel
using the AlphaScreen® assay.22 Previously reported compounds UNC121520 and
UNC66918, 19 were used as positive controls for L3MBTL3 and L3MBTL1, respectively.
UNC107920 was used as a less active control as it binds L3MBTL3 poorly (IC50 = 8.0±3.0
μM). As we were most interested in the selectivity of the compounds for L3MBTL3 against
the other MBT family proteins L3MBTL1 and MBTD1, compounds evaluated at these
proteins were tested at concentrations of up to 300 μM. All other assays were carried out
with a maximal compound concentration of 30 μM. While AlphaScreen® is a suitable
method for the high-throughput screening of compounds, an orthogonal assay such as
isothermal titration calorimetry (ITC) was used to confirm SAR for a representative subset
of compounds.
We initially modified the (pyrrolidinyl)piperidine moiety to a slightly larger 1,4′-
bipiperidine in compound 2 (Table 2). As desired, the L3MBTL1 activity of this compound
decreased to 50±3.2 μM. Unfortunately this small change also resulted in a 9fold drop in
activity for L3MBTL3 which was mirrored in the ITC by a 7-fold loss in activity (Kd = 2.4
μM). This indicates that binding to the L3MBTL3 dimer is primarily mediated by the
interaction of the (pyrrolidinyl)piperidine with the second methyllysine reader domain.
Next, we set out to synthesise compounds of different sizes by modifying the length and
position of the 2-carbon linker. Shortening the linker to a single methylene, in compound 3
resulted in a 4 to 5-fold drop in L3MBTL3 activity (IC50 = 0.35±0.11 μM, Kd = 1.4 μM),
which could be due to a weaker interaction of this compound with either or both of the
domain 1 and domain 2 binding sites of the L3MBTL3 dimer. Lengthening the linker to a 3-
carbon chain in compound 4 maintained L3MBTL3 activity in the Alphascreen® and is
consistent with the ability of a larger molecule like UNC1215 to be accommodated in the
binding site. Compound 4, however, was less active against L3MBTL3 by ITC, which gave
a Kd of 1.84 μM. Moving the 2-carbon chain meta to the piperidine in (compound 5) did not
result in a significantly different IC50 (0.12±0.023 μM) however the ITC showed much
weaker binding (Kd = 2.7 μM) indicating that substitution at this position is not well
tolerated. The shorter methylene linker in the meta position (6) had similar activity to 5.
Confident that the piperidine moiety acts simply as a linker group in both UNC2533 and
UNC1215, we modified the piperidine to a 2-carbon aliphatic chain in compound 7. This
change resulted in a 20-fold loss in potency against L3MBTL3 such that its activity was
similar to the monobasic compound UNC669, and is potentially due to the inability of this
smaller compound to engage both pockets of the dimer. To determine if two basic amines
are critical to maintaining L3MBTL3 activity, we synthesised the corresponding amide,
compound 8, and found that this modification decreased L3MBTL3 activity by more than
30-fold. This loss in activity was also evident by ITC, where only weak binding was
observed (Kd = 38 μM). The same trend was observed when comparing compounds 6 and 9
and is rationalised by the crystal structure of UNC2533, which shows that a strong ionic
interaction occurs between the positively charged nitrogen of the ethyl-pyrrolidine and the
carboxylate of D274 in domain 1. To decrease linker flexibility, the 2-carbon chain was
replaced with the more rigid piperidine in symmetrical compound 10. As a result, the
L3MBTL3 affinity was weakened about 5-fold (0.32±0.11 μM). This loss in activity could
be explained by the UNC2533 crystal structure which shows that it is necessary for the
ethylene linker to adopt a gauche conformation in-order to engage the carboxylate of D274.
A flatter geometry may not be able to achieve this efficiently. As expected, complete
removal of the ethyl pyrrolidine in compound 11, resulted in over a 200 fold loss in
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L3MBTL3 activity (IC50 = 13±1.4 μM), indicating that while this fragment still binds, both
amines are required for high L3MBTL3 potency. In comparison with UNC2533, the activity
of 11 at L3MBTL1 was lower (IC50 = 90±1.1 μM), indicating that the ethyl pyrrolidine is
somewhat responsible for the observed L3MBTL1 binding of UNC2533.
With the knowledge that a two carbon linker is optimal for activity, we continued by
modifying the aromatic core and the ethyl-pyrrolidine of UNC2533 (Table 3). Addition of a
chloro ortho to the 2-carbon linker in compound 22 was tolerated, however no significant
increase in potency was observed. Hypothesizing that we may be able to increase compound
selectivity by designing a covalent inhibitor, we synthesised the electrophilic 3-cyano and 3-
keto compounds 12 and 13 that could be susceptible to nucleophilic attack by the cysteine
thiol present in the domain 1 or domain 2 binding pockets. Both compounds were evaluated
in the same AlphaScreen® assay. After an incubation time of 30 minutes, both modifications
displayed a 5fold drop in potency (Table 3), suggesting that covalent inhibition of
L3MBTL3 seems unlikely and that substitution at the 3-position of the pyrrolidine ring is
sub-optimal for ligand binding. As no significant improvement over UNC2533 was
observed, these compounds were not pursued further.
Further modifications to the ethyl-pyrrolidine by increasing the size of the pyrrolidine ring
to either an azepane (17) or piperidine (18) did not significantly change the L3MBTL3
activity. The L3MBTL3 activity of 18 was confirmed by ITC yielding a Kd of 0.61 μM for
L3MBTL3. Surprisingly, the Kd of 18 for L3MBTL1 was more potent than expected based
on the Alphascreen® results (Kd = 3.3 μM) and is currently under further investigation.
Introduction of a hydrogen bond acceptor to the six-membered ring was originally
hypothesised to have favourable interactions with the tyrosine hydroxyl located at the back
of the domain 1 binding pocket however the inclusion of oxygen in the morpholino
compound 19 was not tolerated. The activity for this compound was weakened by more than
an order of magnitude when compared to the alicyclic compound. This may be due to the
decreased basicity of the morpholino nitrogen compared with the pyrrolidine nitrogen. From
the crystal structure of UNC2533, it is also reasonable to suggest that this may be the result
of an unfavourable electronic clash between the electronegative oxygen atom and the pi
electrons of the nearby Y301. A loss in activity was also observed for the spirocyclic
compounds 20 and 21 which may undergo similar electronic clashes with the binding site.
Decreasing the ring size to an azetidine gave the equipotent compound 14 (versus
UNC2533). Interestingly, this compound was also more selective than UNC1215 against
L3MBTL1 and MBTD1 in our Alphascreen® assay. Further modification to this moiety by
introduction of a difluoro in the 3-position of the azetidine ring in 15 dropped the L3MBTL3
activity to 1 μM. Calculation of the pKa of the azetidine nitrogen in both compounds
revealed that addition of the difluoro decreases the pKa from 10.3 to 7.1 and consequently
weakens the ionic interaction of the pyrrolidine N with D274. The hydrolysed spirocyclic,
compound 16 had a similar activity and selectivity profile to the unsubstituted azetidine (14)
suggesting that the hydroxyl groups are not making new favourable interactions but are also
not interfering with binding. ITC of 16 confirmed the activity of this compound for
L3MBTL3, yielding a Kd of 0.40 μM. The selectivity against L3MBTL1 was also confirmed
by ITC to be 75 fold (Kd = 30 μM).
Conclusions
In summary, we have reported the discovery of a second series of L3MBTL3 inhibitors
based on our original compound UNC2533. These compounds are structurally more
compact than the chemical probe UNC1215 and maintain nanomolar L3MBTL3 potency. In
addition, these compounds have profound selectivity over the Royal family proteins
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L3MBTL1 and MBTD1 as well as a broad range of other methyllysine readers exemplified
in our AlphaScreen® assay. Through structure activity relationship studies, we deduced that
a dibasic amine is necessary for compound potency as both functionalities take part in key
cationpi binding interactions with the L3MBTL3 dimer. Modifications to the
(pyrrolidinyl)piperidine showed that ligand binding is primarily mediated by the interaction
of UNC2533 with the domain 2 reader pocket and that there is little room for variation to
this portion of the molecule. In addition, we found that decreasing the ring size of the ethyl-
pyrrolidine moiety to an ethyl-azetidine was tolerated, giving the equipotent compound 14.
Most importantly, X-ray crystallography of the UNC2533-L3MBTL3 complex showed that
UNC2533 binds the L3MBTL3 dimer as a 2:2 complex and is accommodated by rotation of
the L3MBTL3 dimer interface. This is the first evidence that demonstrates the dynamic
nature of the L3MBTL3 dimer and its ability to change its conformation upon ligand
binding. This has implications for the design of further L3MBTL3 inhibitors and possibly
histone binding.
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Previously reported inhibitors of L3MBTL1 (UNC669) and L3MBTL3, (UNC1215).
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(a) X-ray crystal structure of UNC2533 (1) in complex with L3MBTL3 as a 2:2 complex
(PDB ID: 4L59). UNC2533 is shown in cyan and the two monomers of L3MBTL3 are
colored in green and pink. (b) The binding site of UNC2533 with L3MBTL3 at the dimer
interface showing the key hydrogen bonding interactions of the ligand with residues D381
and D274.
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Alignment of the UNC2533-L3MBTL3 crystal structure (PDB ID: 4L59, cyan) with the
UNC1215-L3MBTL3 crystal structure (PDB ID: 4FL6, grey) using the Kabasch method
implemented in VMD. The monomer on the right is aligned while the other on the left is
misaligned.
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Superimposition of the UNC1215-L3MBTL3 complex (PDB ID: 4FL6, grey carbons) and
the UNC2533-L3MBTL3 complex (PDB ID: 4L59, cyan carbons) (a) view of the domain 2
(methyllysine) binding pocket showing residues in the aligned monomer (b) view of the
domain 1 binding pocket showing residues in the aligned monomer (c)) view of the domain
2 (methyllysine) binding pocket showing the shifted residues in the misaligned monomer (d)
view of the domain 1 (methyllysine) binding pocket showing the shifted residues in the
misaligned monomer.
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Synthetic route to UNC2533 (1). Reagents and conditions: (a) pyrrolidine, K2CO3, CH3CN,
room temperature, 16 h, 58% yield (b) 4-pyrrolidin-1-yl)piperidine, XPhos, Pd2(dba)3,
Cs2CO3, dioxane/water, microwave irradiation, 110°C for 20 min, then 125°C for 3 h, 12%
yield.
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Reagents and conditions: (a) pyrrolidine, TBTU, NEt3, DMF, room temperature, 17 h (b) 4-
pyrrolidin-1-yl)piperidine, RuPhos, RuPhos pre-catalyst, NaOt-Bu, THF, microwave
irradiation, 120°C, 10 min (c) LiAlH4, THF, reflux, 18 h.
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‡It should be noted that the Alphascreen® activities of UNC1215, UNC669 and UNC1079 are slightly different in various
publications due to changes in the assay format – readers should refer to the supplemental information for the exact conditions that
were used for the assays in this publication.
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